CDMO PLATFORM
Agile and flexible CDMO services tailored to your requirements
CAPABILITIES
World-class biologics Contract Development and Manufacturing
Our CDMO services are tailored to your specific manufacturing needs bringing your biologic to clinical trials and to market quickly and efficiently.
+15
years of
experience
7
commercial products
+97%
batch success
rate
Single-use technology and flexible scales
We have streamlined manufacturing processes for high operational efficiency and reduced time-to-market
Double-source manufacturing facilities
Our state-of-the-art production sites in Europe and South America have identical manufacturing configurations for seamless backup and adaptability to demand
Commercial stage CDMO
We have years of expertise bringing biologics to the market ensuring high quality medicines timely reach patients worldwide.
Cutting-edge scalable system
Single-use bioreactors with flexibility
From 2L to 4,000L bioreactors
6,000L bioreactors coming soon
12,000L batches coming soon
Capacity in expansion
From 50,000L to
74,000L total capacity
5 productions lines
+ 1 coming soon
in 3 sites
SERVICES
End-to-end CDMO solutions for efficient clinical and market supply
Our CDMO services are fully integrated, agile and flexible: from cell line development to bulk drug substance. In all our processes we apply high-quality, innovative technologies and on site strong analytical capabilities at our modern facilities to help accelerate your programs and facilitate early market entry.
Early-stage programs
IND ready in 12 months
Late-stage programs
Manufacturing-ready in 18 months
EXPERTISE
Experts in antibodies and antibody-like molecules
Our expertise is in the field of biopharmaceutical development and manufacturing, combined with strong in-house analytical capabilities. Our core competencies are applied to antibody formats.
Antibodies
Monoclonal
Chimeric
Bispecific
FABs
ADCs
Nanobodies
Fusion proteins
Fc Fusions
Multispecific proteins
EXPERTISE
Additional expertise in
hormones
Our infrastructure and manufacturing setup are also prepared to support hormone development projects, with the technical capabilities required to adapt to their specific process and production needs.
Recombinant proteins
Hormones
Enzymes
CASE STUDIES
How we deliver, milestone by milestone
Capacity
Market leadership with Bevacizumab
With uninterrupted manufacturing since 2019, 400+ kg produced in 2022, and 900,000+ vials supplied worldwide in 12 months.
We hold a 25% market share in Europe and hold leading positions in Brazil, Mexico and Argentina.
Agility
Denosumab delivery from day one
We launched Denosumab from day one, demonstrating speed, preparation and cross-functional execution needed to move fast when timing matters most.
